Results of denosumab used in postmenopausal women with osteoporosis
Abstract
The use of monoclonal antibodies in combination therapy is one of the most promising areas in the treatment of osteoporosis. We analyzed the results of combined treatment of postmenopausal osteoporosis with denosumab in combination with calcium preparations and active forms of vitamin D against the background of low levels of vitamin D in blood serum. After 24 months from the start of treatment, the level of vitamin D reached the target values. Significantly decreased pain scores. The mineralization indicators of all the studied localizations have significantly improved compared to the initial data. After 2 years from the start of therapy, bone mineralization indicators reached the range of normal values. The conducted study indicates the high efficiency of the combined treatment of postmenopausal osteoporosis using monoclonal antibodies.
About the Authors
Ya. L. Navmenova
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
I. G. Savasteeva
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
N. F. Chernova
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
T. I. Moskvicheva
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
E. S. Makhlina
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
References
1. Общая характеристика лекарственного препарата Пролиа [Электронный ресурс] Режим доступа: https://rceth.by/NDfiles/instr/10183_13_16_17_18_s.pdf Дата доступа: 01.09.19.
2. Bone, H.G. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension / H.G. Bone, R.B. Wagman, M.L. Brandi //The lancet Diabetes & endocrinology. - 2017. - Vol. 5. - Р. 513-523.
3. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: amulticentre, randomised, double-blind, active-controlled, double-dummy, noninferiority study / K.G. Saag [et al.] // Lancet Diabetes Endocrinol. - 2018. - Vol.6, iss.6. - P.445-454.
4. Opyt primeneniya denosumaba dlya lecheniya postmenopauzal’nogo osteoporoza / E.V.Rudenko [et al.] // Medicinskie novosti. - 2019. - № 10. - Р. 22.
5. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial / C. Recknor [et al.] // Obstet. Gynecol. - 2013. - Vol. 121, No 6. - P. 1291-1299.
6. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy / D.L. Kendler [et al] //j. Bone Miner. Res. - 2010. - Vol. 25. - No 1. - P. 72-81.
7. Roman-Gonzales, A. Pharmacotherapy of bone loss in postmenopausal women: focus on Denosumab / A. Roman-Gonzales, K.E. Ackerman // Clin. Med. - 2009. - No 1. - P.1131-1143.
8. Cummings, S.R. Denosumab for prevention of fractures in postmenopausal women with osteoporosis / S.R. Cummings, J. San Martin, M.R. McClung // The New England journal of medicine. - 2009. - No 361. - Р. 756-765
9. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина Д у взрослых / Е.А. Пирогова [и др.] // Проблемы эндокринологии. - 2016. - Т.62, №4. - С. 60-84.
10. Kanis, J.A. European guidance for the diagnosis and management of osteoporosis in postmenopausal women /j.A. Kanis, N.Burlet, C.Cooper // Osteoporos.Int. - 2008. - No. 19. - Р. 399-428.
11. Использование шкал и анкет в вертебрологии / В.А. Бывальцев [и др.] //Журнал неврологии и психиатрии. - 2011. - №9, Вып.2. - С.51-56.
Review
For citations:
Navmenova Ya.L., Savasteeva I.G., Chernova N.F., Moskvicheva T.I., Makhlina E.S. Results of denosumab used in postmenopausal women with osteoporosis. Medical and Biological Problems of Life Activity. 2022;(1):111-116. (In Russ.)
Views: 108
Email this article 